Attention: Fluid Overload Is Destroying Your Patients’ Quality of Life

Think of the 68-year-old man with chronic heart failure who cannot walk from the bedroom to the kitchen without stopping because of dyspnoea. Think of the 55-year-old woman with malignant ascites who feels bloated, nauseated and unable to eat. Think of the patient in ICU with oliguric acute kidney injury and pulmonary oedema, or the patient with raised intracranial pressure after a brain injury. These are the patients who fill Australian hospital beds, general practice waiting rooms and oncology day units every day.

The shared clinical problem is often excess extracellular fluid. Fluid overload increases hospitalisation, reduces exercise tolerance, impairs organ function and steals independence. In Australia, fluid overload from heart failure alone accounts for thousands of admissions each year. The loop diuretic furosemide (frusemide) remains one of the most effective, affordable and rapidly acting tools to relieve this burden.

If you are looking for a medicine that acts within minutes, is PBS-listed, is available in every Australian hospital and community pharmacy, and can be used across cardiology, nephrology, oncology, neurology and intensive care, furosemide deserves a fresh look.

Interest: How Furosemide Works in the Body

Furosemide is a loop diuretic. Its primary site of action is the thick ascending limb of the loop of Henle, where it inhibits the sodium-potassium-chloride (Na⁺-K⁺-2Cl⁻) cotransporter. This prevents reabsorption of sodium, chloride and potassium, causing a powerful natriuresis and diuresis. The result is a rapid reduction in circulating plasma volume, venous return, preload and oedema.

The drug has a fast onset: after intravenous administration, diuresis begins within 5–15 minutes; after oral administration, within 30–60 minutes. The effect lasts approximately 4–6 hours, which is useful for adjusting doses and avoiding overnight diuresis in elderly patients.

Effect on the Renin-Angiotensin System (RAAS)

Furosemide has a complex and clinically important interaction with the renin-angiotensin-aldosterone system. By reducing sodium chloride delivery to the macula densa and lowering renal perfusion pressure, furosemide activates the RAAS. This leads to increased renin release, angiotensin II production and aldosterone secretion. In the short term, this helps maintain blood pressure and glomerular filtration rate. In the longer term, however, RAAS activation can cause sodium retention, potassium loss and diuretic resistance.

This is why furosemide is rarely used alone in chronic heart failure or cirrhosis. It is best combined with an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker or aldosterone antagonist. The combination improves outcomes and helps overcome the compensatory sodium retention induced by diuretic therapy.

Desire: Clinical Answers to Difficult Scenarios

Furosemide is not just a diuretic. It is a versatile drug that can be used in some of the most challenging inpatient and outpatient situations. Below are answers to common clinical questions, with practical dosing guidance.

1. What is the role of furosemide in acute kidney injury (AKI)?

Furosemide does not prevent AKI, and it does not improve renal recovery when used routinely in oliguric patients. Its role in AKI is to manage volume overload, particularly when the patient has pulmonary oedema, heart failure or severe hypertension. In selected patients, a trial of furosemide may convert oliguric AKI into non-oliguric AKI, making fluid balance easier to manage and allowing better nutrition and medication administration. However, high doses in a hypovolaemic patient can worsen renal perfusion and should be avoided.

Practical approach: In a patient with AKI and evidence of fluid overload, give an intravenous bolus of 40–80 mg. If the response is inadequate, consider a continuous infusion of 10–20 mg/hour after the bolus, titrated to urine output and clinical response. Always reassess volume status before increasing the dose. Monitor creatinine, electrolytes and urine output closely.

2. How to dose furosemide in patients with ascites due to malignancy?

Malignant ascites can be extremely distressing. Fluid accumulation causes abdominal distension, early satiety, nausea, dyspnoea and reduced mobility. Diuretics are most effective when the ascites is due to portal hypertension, which often occurs with liver metastases. A useful marker is the serum-ascites albumin gradient; a value above 1.1 g/dL suggests portal hypertension and a better response to diuretics.

Dosing: Start with oral furosemide 40 mg once daily, usually combined with spironolactone 100 mg once daily. Titrate every 3–5 days according to weight loss, aiming for no more than 0.5 kg of weight loss per day in patients without peripheral oedema. The furosemide dose can be increased to 80–120 mg daily, and in selected patients up to 160 mg daily, but careful monitoring is essential. Avoid aggressive diuresis because it can precipitate renal impairment, hypotension and hepatorenal syndrome.

If the patient cannot tolerate oral therapy or has tense ascites requiring rapid relief, consider intravenous furosemide 40–80 mg. Always monitor weight, renal function, serum sodium and potassium.

3. What is the effect of furosemide on intracranial pressure?

Furosemide can lower intracranial pressure (ICP) through several mechanisms. It reduces total body water, decreases cerebrospinal fluid formation and may reduce cerebral oedema. In neurocritical care, furosemide is sometimes used as an adjunct to osmotic agents such as mannitol or hypertonic saline. It may help prolong the ICP-lowering effect of mannitol and prevent rebound cerebral oedema.

However, furosemide is not first-line therapy for raised ICP. It can cause hypovolaemia and hypotension, which may reduce cerebral perfusion pressure and worsen neurological outcomes if used injudiciously.

Practical use: When used, give intravenous furosemide 0.5–1 mg/kg as an adjunct to mannitol in a monitored environment. Monitor serum sodium, osmolality, blood pressure and urine output. The goal is to reduce ICP while maintaining adequate cerebral perfusion.

4. How to use furosemide in patients with nephrogenic diabetes insipidus?

Nephrogenic diabetes insipidus (NDI) causes massive polyuria and polydipsia because the kidneys do not respond to antidiuretic hormone. The preferred diuretics in NDI are thiazide diuretics, not loop diuretics. Thiazides cause mild volume contraction, which increases proximal tubular sodium and water reabsorption and reduces urine output.

Furosemide is generally not recommended as first-line treatment for NDI because it can impair the medullary concentration gradient and worsen the concentrating defect, potentially increasing urine output. However, furosemide may still be needed in a patient with NDI who has a separate indication such as heart failure, pulmonary oedema or severe chronic kidney disease.

If you must use furosemide in NDI: Use the lowest effective dose, start with 20–40 mg orally or intravenously, and monitor urine output, serum sodium and volume status carefully. Avoid dehydration, and involve a nephrologist or endocrinologist for complex cases.

5. Can furosemide cause leukopenia?

Yes, although it is rare. Furosemide has been associated with blood dyscrasias, including leukopenia, agranulocytosis, thrombocytopenia and aplastic anaemia. The exact incidence is very low, but the potential severity means clinicians should remain alert.

Advise patients to seek medical review if they develop unexplained fever, sore throat, mouth ulcers, recurrent infections or unusual bruising while taking furosemide. If leukopenia or another blood dyscrasia is suspected, stop the drug and arrange a full blood count. In most cases, the white cell count recovers after discontinuation.

6. Can furosemide be used in patients with hyponatremic encephalopathy?

Hyponatremic encephalopathy is a medical emergency. The primary treatment is hypertonic saline to rapidly raise serum sodium and reduce cerebral oedema. Furosemide is not a substitute for hypertonic saline. However, furosemide can be a useful adjunct in selected patients, particularly those with coexisting volume overload or heart failure, because it can help mobilise free water and prevent pulmonary oedema during hypertonic saline administration.

In patients with euvolaemic or hypervolaemic hyponatraemia, such as SIADH, a loop diuretic may increase free water excretion and assist sodium correction. If used, give intravenous furosemide 20–40 mg alongside hypertonic saline in an intensive care or high-dependency setting. Check serum sodium every 2–4 hours to avoid overly rapid correction. The maximum safe correction is generally 8–10 mmol/L over 24 hours. Overcorrection can cause osmotic demyelination syndrome, a devastating neurological complication.

Key message: Use furosemide as an adjunct, not as primary therapy, in hyponatremic encephalopathy.

The Patient Pain Points Furosemide Addresses

For patients over 30, fluid overload causes real suffering. Furosemide can relieve:

• Breathlessness and orthopnoea from heart failure and pulmonary oedema.
• Swollen legs, ankles and abdomen from cardiac, hepatic or renal disease.
• Fatigue and reduced exercise tolerance caused by excess fluid and increased cardiac workload.
• Frequent hospital admissions for decompensated heart failure or ascites.
• Discomfort and poor quality of life in malignant ascites and advanced organ failure.

When used correctly, furosemide acts quickly, is inexpensive and can be titrated to individual needs. It empowers patients to manage their fluid balance at home, reducing emergency presentations and preserving independence.

Action: Make Furosemide a Confident Part of Your Prescribing Toolkit

Furosemide is already on the PBS and is one of the most accessible medicines in Australia. It is available as oral tablets (20 mg, 40 mg, 500 mg), oral liquid and intravenous injection. In acute settings, it can be given as a bolus or continuous infusion. In chronic care, it can be used once or twice daily to fit the patient’s lifestyle and minimise nocturia.

Review your current patients who are struggling with fluid overload, heart failure, renal impairment, malignant ascites or raised ICP. Ask yourself whether a loop diuretic could relieve their symptoms today. If you are not already prescribing furosemide where indicated, you may be missing a simple, effective opportunity to improve quality of life and reduce hospitalisation.

Ensure your practice, ward or hospital pharmacy is stocked with furosemide in both oral and injectable forms. Educate your patients about the importance of weight monitoring, salt restriction and electrolyte review. Use furosemide as part of a comprehensive management plan, and combine it with RAAS blockers where appropriate to improve long-term outcomes.

Furosemide is not a new or glamorous drug, but it is one of the most reliable tools in medicine. For the breathless patient, the swollen patient, the patient with ascites or pulmonary oedema, furosemide can be the difference between hospital and home. Add it to your prescribing toolkit — and use it with confidence.